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Background: Influenza infections result in both inappropriate and appropriate antibiotic prescribing. There is a
huge burden of both influenza and infections caused by antimicrobial-resistant pathogens in Africa. Influenza
vaccines have the potential to reduce appropriate antibiotic use, through reduction of secondary bacterial infec-
tions, as well as to reduce levels of influenzamisdiagnosed and treated as a bacterial infection (inappropriate).
Objectives: To estimate potential reductions in antibiotic use that are achievable by introducing an influenza
vaccine into various African settings.
Methods: Influenza incidencewas combinedwith population size, vaccine and health system characteristics.
Results: We estimated that the direct impact of vaccination could avert more than 390 prescriptions per
100000 population per year if a 50% efficacious influenza vaccine at 30% coverage was introduced to adults
.65years old in South Africa or children 2–5years old in Senegal. Across Africa, purely through reducing the
number of severe acute respiratory infections, the same vaccine characteristics could avert at least 24000 anti-
biotic prescriptions per year if given to children,5 years old.
Conclusions: The introduction of an influenza vaccine into multiple African settings could have a dramatic indir-
ect impact on antibiotic usage. Our values are limited underestimates, capturing only the direct impact of vaccin-
ation in a few settings and risk groups. This is owing to the huge lack of epidemiological information on antibiotic
use and influenza in Africa. However, it is likely that influenza vaccination in Africa could substantially impact
antibiotic usage in addition to influenza-relatedmortality andmorbidity.
Introduction
Antimicrobial resistance (AMR) is a global concern. The rise in re-
sistance, in part, is attributed to inappropriate use of antibiotics
such as for misdiagnosed viral infections, including influenza.
Currently, the capacity to tackle misdiagnosis is lacking in many
low- andmiddle-income countries (LMICs). A recent review of AMR
in Africa highlighted high levels of resistance to antibiotics com-
monly used for respiratory tract infections.1 Moreover, West and
Southern Africa had among the greatest increases globally in per
person antibiotic consumption between 2000and 2010.2
Influenza infections result in increased antibiotic prescribing to
treat secondary bacterial infections (appropriate) and primary
influenza cases misdiagnosed as bacterial infections (inappropri-
ate). An indirect benefit of influenza vaccination could be to reduce
antimicrobial prescribing and, ultimately, AMR. However, both the
burden of influenza and use of influenza vaccines in Africa have
been neglected. A study of 15 African countries demonstrated
that influenza accounted for 21.7% of influenza-like illness (ILI)
and 10.1% of severe acute respiratory infection (SARI) cases.3 A re-
cent systematic analysis found that the per capita influenza-
associated hospitalization rate in children ,5years old was .3-
fold higher in Africa comparedwith Europe.4
In 2012, the WHO Strategic Advisory Group of Experts recom-
mended influenza vaccination in key high-risk groups: pregnant
women (with potential protection for the neonate), children aged
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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6–59months, the elderly, healthcare workers and those with spe-
cific chronic medical conditions. However, a recent analysis found
that only three African countries (of 47 WHOmember states) had
implemented seasonal influenza vaccine policies.5
TheGlobal Alliance for Vaccines and Immunization (GAVI) foun-
dation, a major vaccine funder, has proposed immunization as a
key strategy in combating AMR, but one which requires more re-
search to guide intervention prioritization.6 The potential for
influenza vaccines to reduce antibiotic prescribing has been deter-
mined in only one study from Ontario, Canada, in which an associ-
ation between a 64% reduction in antibiotic prescriptions and roll-
out of a universal influenza immunization programme was
demonstrated.7 The impact of influenza vaccine roll-out on anti-
biotic usage in Africa is currently unknown.
In the absence of direct trial data, we combined data from a
range of sources to predict the potential number of antibiotic pre-
scriptions that could be directly avoided by influenza vaccine roll-
out in various African populations, taking into account variability in
healthcare (and therefore antibiotic) availability and vaccine
coverage. These estimates should stimulate further discussion
and research on the wider benefits of influenza vaccine roll-out in
African countries with currently low influenza vaccine coverage,
high influenza burden, high level of antibiotic use and rising levels
of AMR.
Methods
Data on influenza incidence
There is limited information onmany aspects required to comprehensively
estimate the impact of influenza vaccination on antibiotic prescribing
acrossAfrica. Hence,we includedonly thenumber of (i) appropriate antibiot-
ic prescriptions following SARI and (ii) inappropriate antibiotic prescriptions
following influenza-related ILI in example settings. We identified studies
that provided robust estimates of influenza-related ILI or SARI in different
high-risk groups from a number of African countries, either via attack rates
in placebo recipients enrolled in randomized clinical trials or epidemiological
studies and systematic reviews [Table S1 (see Supplementary data—Part I,
available as Supplementary data at JAC Online)]. We did not include the in-
direct impact of vaccination on secondary influenza cases owing to a lack of
data on influenza transmission dynamics fromAfrican settings.
Calculating antibiotic use
We split antibiotic use into two components: (i) likelihood that someone
with an ILI or SARIwould be prescribed antibiotics; and (ii) likely provision of
healthcare and antibiotics in a setting. These weremultiplied to give a level
of antibiotic prescribing.
For (i) we assumed that SARI cases would usually fulfil criteria in clinical
guidelines for prescribing antibiotics (e.g. WHO integrated management of
childhood illness) and therefore that, if available, 100%would beprescribed
antibiotics. The available literature suggests that the proportion with ILI
that receive an (inappropriate) antibiotic is higher in LMICs than in high-in-
come settings (see Supplementary data—Part I), hencewe assumed in our
calculations that 70%of influenza-related ILIwould inappropriately bepre-
scribed antibiotics.
We assumed that coverage of healthcare provision and antibiotic avail-
ability was 50%. Thus, even if 100% of SARI patients would ordinarily be
given antibiotics, only 50% of them would receive antibiotics. The aim of
this parameter was to reflect health system failings in LMIC settings where
antibiotics may not always be available, despite prescription, or where
SARI-relateddeaths occur outside a healthcare setting.
Population size estimates
Data from the World Bank for 2015 were used to generate population size
estimates (see Supplementary data—Part I).
Vaccine characteristics and coverage
Weassumed vaccine effectivenesswas 50% based on various international
estimates.8 We considered a low vaccine coverage of 30%. In
Supplementary data—Part II we provide estimates for higher healthcare
provision and antibiotic availability (80%) and 90% vaccine coverage. The
high vaccine coverage figure was based on studies in The Gambia, where
uptake of infant immunizations reaches.90% inmany cases.9
Results
The overall estimates for the impact of an influenza vaccine pro-
gramme targeting key high-risk groups are shown in Table 1. With
low vaccine coverage (30%) and antibiotic availability at 50%, the
number of prescriptions that could be averted by targeting each
risk group is between 15 and 945 per 100000 population per year.
Of the populations considered, the lowest estimates come from
targeting those.65years old in Ghana, the highest from targeting
adults .65years old in South Africa or children 2–5years old in
Senegal. In a corresponding measure, 5–315 antibiotic prescrip-
tions could be averted per 10000 vaccinations.
Two studies provided estimates for SARI incidence only in chil-
dren,5years old across Africa.4,10 Using these, we estimated that
just avoiding appropriate antibiotic use for these most serious
cases with the introduction of influenza vaccine at 30% coverage
could prevent at least 24000 antibiotic prescriptions per year [13
(95%CI 7–26) per 100000 population per year].
Discussion
We aimed to estimate the impact of influenza vaccines on anti-
biotic use in Africa, using the current limited data available. Our
conservative direct impact estimates suggest that a large number
of antibiotic prescriptions could be averted across Africa each year,
evenwith low coverage of an influenza vaccine.
Our estimates were limited by a lack of data. More data are
needed on both influenza and secondary bacterial infection inci-
dence, as well as antibiotic exposure levels (by age) to allow calcu-
lation of ‘influenza-attributable prescribing’.11 In addition,
determining influenza vaccine impact would involve modelling
vaccine campaign timing (with varying influenza seasonality
across Africa) and variation in coverage in different risk popula-
tions. Vaccine efficacy may also vary in different risk populations
(e.g. due to immunosenescence), aswell as due to seasonality and
influenza antigenic drift. Moreover, high HIV prevalence in certain
settings, alongside substantial variation in access to healthcare
(and hence antibiotic prescribing) could make estimates highly
setting-specific. We included an antibiotic ‘availability’ parameter,
but to our knowledge, there are no studies that explore the relative
ease of antibiotic accessibility across Africa (e.g. impact of unsanc-
tioned providers, health system quality or rural/economic setting)
or health-seeking behaviour differences.
Our evaluation is an underestimate, not only as we likely use
conservative vaccine coverage (30%) and antibiotic availability
(50%) values, but as we do not include the indirect impact of
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vaccination on secondary cases of influenza. Reduction in influ-
enza transmission in the community by vaccinating high-risk
groups may significantly enhance the impact observed. A recent
modelling study of the German population suggested that 4–7%
as many influenza cases are prevented among non-vaccinated
individuals as among vaccinees.12Owing to a lack of data, our esti-
mates also only considered the number of ILI or SARI
cases averted by the vaccine. Only a minority of risk groups
(e.g. 65years old in Ghana) had data on both ILI and SARI inci-
dence (Table 1). Hence our estimates are an underestimate of
even the combined direct impact of vaccination.
Several agencies (e.g. GAVI) are now calling for the use of vac-
cines to help in the prevention of AMR.11 However, as in our work
here, although the impact on antibiotic prescribing can be esti-
mated, the jump to impact on AMR is challenging to make.13
Without this link, the likely dramatic impact of influenza vaccine
on antibiotic usage and subsequent AMR levels in Africa cannot
be estimated.
The estimateswemake here should be expanded asmore data
on influenza and antibiotic use become available. Importantly, fu-
ture trials in LMICs should consider linking outcomes across public
healthmeasures; influenza vaccine trials could bedesigned to cap-
ture impact on antibiotic usage in addition to preventing influenza
infections.
Influenza vaccines could have a dramatic impact on morbidity
and mortality in Africa. The reasons for the lack of influenza vac-
cine programmes across the continent aremultifactorial, including
health economic ones. Yet policy decisions are oftenmade by con-
sidering prevention of influenza infections as the sole beneficial
outcome. Although public health interventions such as vaccination
are costly, as highlighted by our estimates, the wider benefits may
be substantial and, with increasing evidence, should be included
as key considerations.
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